$NTHIOct 6, 2026, 9:02 AM ETAI processed
NTHI faces two near-term FDA Type B meetings for NEO100 (Oct) and NEO212 (Nov 17)
AI Summary
NeOnc (NTHI) has an anticipated FDA End-of-Phase 2 Type B discussion for intranasal NEO100 expected in October and a scheduled End-of-Phase 1 Type B meeting for oral NEO212 on Nov. 17, which could clarify trial design, endpoints, and path to pivotal studies. NEO100 reported encouraging Phase 2a results (24 patients: 6‑month PFS 48.9% vs 20% historical benchmark; median OS 26.09 months), but the dataset is small and the article noting these catalysts was a paid editorial, so outcomes remain uncertain until FDA feedback and further trials.
Positives
- NEO100 Phase 2a met its primary endpoint in 24 patients (6‑month PFS 48.9% vs 20% historical benchmark; median OS 26.09 months)
- Upcoming FDA Type B meetings (anticipated Oct for NEO100; scheduled Nov 17 for NEO212) could define next steps toward pivotal trials
- NEO100 holds Orphan Drug, Fast Track and Rare Pediatric Disease designations and analyst coverage has expanded (e.g., Roth Buy initiation)
Negatives
- Efficacy results are from a small, open‑label 24‑patient Phase 2a cohort — limited and preliminary
- The article is a paid editorial funded by the company, introducing potential bias in the presentation
- FDA meetings are advisory discussions; they do not guarantee approval or definitive advancement and outcomes are uncertain